Step 1: Confirm your cancer type
If you have prostate cancer
Lutetium therapy (Lu-177 PSMA therapy) may be an option if:
- Your cancer has spread beyond the prostate (metastatic disease).
- It has progressed despite hormone therapy (castration-resistant).
- You've typically received an androgen receptor pathway inhibitor (enzalutamide or abiraterone) and either taxane chemotherapy (docetaxel/cabazitaxel) or you can't tolerate it.
- The 2024 PSMAfore trial supports use earlier in some patients — discuss with your oncologist.
Next step: ask your oncologist about a PSMA PET scan if you haven't had one.
If you have a neuroendocrine tumor (NET)
Lutetium therapy (Lu-177 DOTATATE therapy) may be an option if:
- Your tumor is well- or moderately-differentiated (Grade 1 or 2; Ki-67 ≤ 20%).
- It arises from the gastroenteropancreatic system (gut, pancreas, sometimes lung).
- It has progressed despite first-line somatostatin analog therapy (octreotide LAR or lanreotide).
- The 2024 NETTER-2 trial supports first-line use in Grade 2/3 — discuss with your oncologist.
Next step: ask your oncologist about a Ga-68 DOTATATE PET (or similar somatostatin receptor scan) if you haven't had one.
If you have another cancer
Lutetium therapies for other cancers (sarcomas, pancreatic adenocarcinoma, meningioma, etc.) are investigational — meaning available primarily through clinical trials, not approved standard care. If you have one of these, ask about clinical trial eligibility specifically.
Read about emerging Lutetium therapies →
Step 2: The decisive test — your scan
The single most important question is: does your cancer show uptake on the appropriate scan?
- Prostate cancer: PSMA PET (Ga-68 PSMA or F-18 PSMA)
- NETs: Ga-68 DOTATATE PET (or similar Octreotide receptor scan)
If your scan shows clear “hot” spots at your known tumor sites, you're a candidate. If uptake is weak or absent, Lutetium therapy is unlikely to help and your oncologist will likely recommend something else.
Step 3: Your other health factors
Even with the right scan, eligibility requires:
- Adequate kidney function (eGFR ≥ 30 mL/min for Lu-177 PSMA therapy; thresholds for Lu-177 DOTATATE therapy similar)
- Adequate bone marrow (hemoglobin ≥ 9 g/dL, platelets ≥ 75,000, neutrophils ≥ 1,500/µL — approximations)
- Performance status ECOG 0–2 (you can walk and do most self-care)
- No active uncontrolled infections or other serious medical issues
Step 4: Your goals
Lutetium therapy is a treatment that, for many patients, extends life and improves quality of life. The decision to start (or continue) deserves a frank conversation about your goals:
- Are you focused on maximum disease control, even with some treatment burden?
- Are you focused on quality of life — fewer side effects, less time at hospitals?
- Some of both? At what trade-off?
There's no right answer. Lutetium therapy serves all of these goals in different cases. The clearer you are about your goals, the better your oncologist can advise.
Questions to bring to your oncology appointment
Special situations
I'm considering traveling internationally for treatment
For Indian patients, Lutetium therapy is widely available in India and is a cost-effective option. For international patients, India offers the most affordable high-quality option globally. See our international patient guide for visa, logistics, and total cost planning.
I'm a caregiver, not the patient
Most of our readers are caregivers — spouses, children, adult children of older parents. Lutetium therapy is a particularly caregiver-friendly treatment because the patient comes home the same day after each infusion. Plan to be available for the first few days after each cycle. Caregiver guide →
I've been told I don't qualify but I'm not sure
Eligibility criteria can sometimes be interpreted differently across centers and specialists. If your oncologist hasn't mentioned Lutetium therapy and you think you might qualify, a second opinion is worth seeking. A navigator can help you find a specialist who can give you a fresh look.